Condition: Adult Congenital Heart Disease · Heart Failure · Sponsor: Anita Saraf
The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).
This description comes directly from the study's public registry record.
Anita Saraf, MD, PhD · 4128648661 · sarafap@upmc.edu
Morgan Hindes · mhindes@chp.edu
Always discuss trial participation with your own doctor first.
| Magee Women's Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
| Presbyterian Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
| Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06260059